Connection

Andrew Kraft to Receptor, IGF Type 1

Back to Details
This is a "connection" page, showing publications Andrew Kraft has written about Receptor, IGF Type 1.
Andrew Kraft
Connection Strength
0.027
Receptor, IGF Type 1
  1. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.